Lisinopril is used for treating high blood pressure alone or with other medicines.
Price of lisinopril 10 mg /d versus placebo) and the incidence of primary outcomes: falls â‰¥3 mo, unstable angina, cardiac arrest, nonfatal MI, and death. In the peri-protocol population, incidence of falls was significantly improved in the peri-protocol population compared with controls (hazard ratio, 0.60; 95% CI, 0.30-0.98). There were no changes in other the primary outcomes.
Conclusions and Relevance The randomized RCT demonstrated a significant reduction in acute myocardial infarction and cardiovascular death in the elderly with no changes in the overall incidence of falls. As October 2013, the peri-protocol population was free from clinically-significant adverse cardiovascular outcomes.
Trial Registration clinicaltrials.gov Identifier: NCT02081783
Obesity and overweight in older adults are increasing worldwide.1,2 The prevalence of overweight and obesity among older adults is projected to increase by 1.5% between 2010 and 2030,3 may in part be attributed to an aging population with more advanced frailty and chronic conditions that increase the risk for hospitalization and death.4 This underscores the importance of treating older patients with obesity-mediated conditions.
Evidence is mixed on whether statins can improve risk for cardiovascular disease and other age-related morbidities.5,6 However, a Cochrane review7 concluded that among patients taking statins, there was no benefit compared with placebo in patients at least one major cardiovascular event (MI, stroke, or death) and lisinopril hctz 20 12.5 mg price no adverse effects. The review also found that among patients treated with statins and those not, there was a moderate beneficial effect on the prevalence of diabetes mellitus in the statin subgroups versus placebo. In addition, it found no adverse effects in patients who did not take the statin. It should be noted that the only other randomized controlled trial of a statin for the prevention of cardiovascular events, SPRINT trial,8 found a significant improvement cost of lisinopril 10 mg without insurance in total mortality and incidence of adverse events in participants without heart failure.
The objective of this large RCT8 evaluated the effects of short-term (12 wk) treatment with lisinopril 10 mg/d on coronary events, hypertension, and blood pressure.
Study Design and Primary Outcomes
The SPRINT study is a randomized pla